logo

Alkermes Plc (ALKS)



Trade ALKS now with
  Date
  Headline
2/14/2018 7:02:21 AM Alkermes Q4 Net Loss $9.8 Mln Or $0.06/shr Vs. Net Loss $21.1 Mln Or $0.14/shr Last Year
11/27/2017 7:00:48 AM Biogen And Alkermes Announce License And Collaboration Agreement To Develop And Commercialize ALKS 8700
11/16/2017 7:05:29 AM Alkermes Says NDA For Investigational Product Designed For Initiation Onto ARISTADA Accepted For Filing By US FDA
11/14/2017 8:03:23 PM VIVITROL And Value Of MAT For Opioid Dependence Featured In Study Sponsored By National Institute On Drug Abuse
11/8/2017 7:06:52 AM Alkermes Reports Presentation Of Positive Preclinical Data On Immuno-oncology Drug Candidate, ALKS 4230
10/27/2017 9:31:15 AM Alkermes Presents Data Showing Safety And Gastrointestinal Tolerability Profile Of ALKS 8700
10/26/2017 7:07:20 AM Alkermes Plc Q3 Total Revenues Up 21% Year-Over-Year To $217.4 Mln
10/26/2017 7:06:55 AM Alkermes Unveils Investigational Product Designed For Initiation Onto ARISTADA For Schizophrenia